SC
LGND icon

Schubert & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Schubert & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$515 – 846
2023
Q1 		$515 Hold
7
– – ﹤0.01% 1406
2022
Q4 		$468 Sell
7
-6
-46% -$390 ﹤0.01% 1404
2022
Q3 		$1K Buy
13
+2
+18% +$118 ﹤0.01% 1155
2022
Q2 		$1K Buy
11
+8
+267% +$454 ﹤0.01% 1174
2022
Q1 		$0 Sell
3
-2
-40% -$145 ﹤0.01% 1220
2021
Q4 		$0 Buy
+5
New +$462 ﹤0.01% 1159

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Schubert & Co's LGND Position: Q2 2023 in Review

Schubert & Co sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 7 shares — an estimated $515 sold.

Schubert & Co first reported a position in LGND in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • Schubert & Co reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 7 Ligand Pharmaceuticals shares in Q2 2023, an estimated $515.
  • Schubert & Co first reported a position in Ligand Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Ligand Pharmaceuticals position peaked at $1K in Q3 2022.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.